CN111228158A - 一种祛斑组合物 - Google Patents
一种祛斑组合物 Download PDFInfo
- Publication number
- CN111228158A CN111228158A CN202010226078.0A CN202010226078A CN111228158A CN 111228158 A CN111228158 A CN 111228158A CN 202010226078 A CN202010226078 A CN 202010226078A CN 111228158 A CN111228158 A CN 111228158A
- Authority
- CN
- China
- Prior art keywords
- removing composition
- freckle
- skin
- salicylic acid
- spot
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000003351 Melanosis Diseases 0.000 title claims abstract description 39
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims abstract description 40
- 239000000284 extract Substances 0.000 claims abstract description 21
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229960004889 salicylic acid Drugs 0.000 claims abstract description 20
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 claims abstract description 14
- 229960003232 troxerutin Drugs 0.000 claims abstract description 14
- CSHZYWUPJWVTMQ-UHFFFAOYSA-N 4-n-Butylresorcinol Chemical compound CCCCC1=CC=C(O)C=C1O CSHZYWUPJWVTMQ-UHFFFAOYSA-N 0.000 claims abstract description 5
- 241000028204 Vincetoxicum atratum Species 0.000 claims description 22
- 239000000243 solution Substances 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 11
- 238000002791 soaking Methods 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 7
- 239000002537 cosmetic Substances 0.000 claims description 6
- 239000004744 fabric Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 239000003906 humectant Substances 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 4
- 239000002562 thickening agent Substances 0.000 claims description 4
- 229920000858 Cyclodextrin Polymers 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 230000001815 facial effect Effects 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 239000000463 material Substances 0.000 claims 1
- 210000003491 skin Anatomy 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 17
- 238000002474 experimental method Methods 0.000 abstract description 9
- 239000004480 active ingredient Substances 0.000 abstract description 6
- 210000002752 melanocyte Anatomy 0.000 abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 5
- 230000008859 change Effects 0.000 abstract description 4
- 230000000630 rising effect Effects 0.000 abstract description 3
- 238000011156 evaluation Methods 0.000 abstract description 2
- 230000007794 irritation Effects 0.000 abstract 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 19
- 239000000523 sample Substances 0.000 description 15
- 102000003425 Tyrosinase Human genes 0.000 description 13
- 108060008724 Tyrosinase Proteins 0.000 description 13
- 229920001577 copolymer Polymers 0.000 description 13
- 241000700159 Rattus Species 0.000 description 9
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 8
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 8
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 7
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- 239000004721 Polyphenylene oxide Substances 0.000 description 6
- 229920002385 Sodium hyaluronate Polymers 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 229920000570 polyether Polymers 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 229940010747 sodium hyaluronate Drugs 0.000 description 6
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 5
- 108010020346 Polyglutamic Acid Proteins 0.000 description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- ZJXZSIYSNXKHEA-UHFFFAOYSA-N ethyl dihydrogen phosphate Chemical compound CCOP(O)(O)=O ZJXZSIYSNXKHEA-UHFFFAOYSA-N 0.000 description 5
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 5
- -1 polyethylene Polymers 0.000 description 5
- 229940078492 ppg-17 Drugs 0.000 description 5
- 229920001285 xanthan gum Polymers 0.000 description 5
- 235000010493 xanthan gum Nutrition 0.000 description 5
- 239000000230 xanthan gum Substances 0.000 description 5
- 229940082509 xanthan gum Drugs 0.000 description 5
- MXOAEAUPQDYUQM-QMMMGPOBSA-N (S)-chlorphenesin Chemical compound OC[C@H](O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-QMMMGPOBSA-N 0.000 description 4
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 description 4
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 229960003993 chlorphenesin Drugs 0.000 description 4
- 238000007865 diluting Methods 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 4
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 4
- 229960002216 methylparaben Drugs 0.000 description 4
- 229960005323 phenoxyethanol Drugs 0.000 description 4
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 3
- 229940035437 1,3-propanediol Drugs 0.000 description 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 3
- 241001530056 Athelia rolfsii Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 3
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 3
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000002087 whitening effect Effects 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 description 2
- ZEYHEAKUIGZSGI-UHFFFAOYSA-N 4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1 ZEYHEAKUIGZSGI-UHFFFAOYSA-N 0.000 description 2
- 241000206575 Chondrus crispus Species 0.000 description 2
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- VJNCICVKUHKIIV-UHFFFAOYSA-N dopachrome Chemical compound O=C1C(=O)C=C2NC(C(=O)O)CC2=C1 VJNCICVKUHKIIV-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 229940087068 glyceryl caprylate Drugs 0.000 description 2
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000008099 melanin synthesis Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- AEIJTFQOBWATKX-UHFFFAOYSA-N octane-1,2-diol Chemical compound CCCCCCC(O)CO AEIJTFQOBWATKX-UHFFFAOYSA-N 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- VIYKYVYAKVNDPS-HKGPVOKGSA-N (2s)-2-azanyl-3-[3,4-bis(oxidanyl)phenyl]propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 VIYKYVYAKVNDPS-HKGPVOKGSA-N 0.000 description 1
- 229940015975 1,2-hexanediol Drugs 0.000 description 1
- PQUXFUBNSYCQAL-UHFFFAOYSA-N 1-(2,3-difluorophenyl)ethanone Chemical compound CC(=O)C1=CC=CC(F)=C1F PQUXFUBNSYCQAL-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- XYTHHAXRVHHXKO-JIUYZRCGSA-N 18-[(2r,3s,4r,5r)-4,5-dihydroxy-2-(hydroxymethyl)-6-methoxyoxan-3-yl]oxyoctadecanoic acid;ethanol Chemical compound CCO.COC1O[C@H](CO)[C@@H](OCCCCCCCCCCCCCCCCCC(O)=O)[C@H](O)[C@H]1O XYTHHAXRVHHXKO-JIUYZRCGSA-N 0.000 description 1
- PPVDHXWQWABSBC-UHFFFAOYSA-N 2-(2,6-diethyl-4-hydroxy-3,5-dimethoxyphenyl)-2-hexyl-1,3-dioxane-4,6-dione Chemical compound CCC=1C(OC)=C(O)C(OC)=C(CC)C=1C1(CCCCCC)OC(=O)CC(=O)O1 PPVDHXWQWABSBC-UHFFFAOYSA-N 0.000 description 1
- RMTFNDVZYPHUEF-XZBKPIIZSA-N 3-O-methyl-D-glucose Chemical compound O=C[C@H](O)[C@@H](OC)[C@H](O)[C@H](O)CO RMTFNDVZYPHUEF-XZBKPIIZSA-N 0.000 description 1
- XPFCZYUVICHKDS-UHFFFAOYSA-N 3-methylbutane-1,3-diol Chemical compound CC(C)(O)CCO XPFCZYUVICHKDS-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 235000016425 Arthrospira platensis Nutrition 0.000 description 1
- 240000002900 Arthrospira platensis Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 241000218378 Magnolia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241001506047 Tremella Species 0.000 description 1
- 241000908178 Tremella fuciformis Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 101710147108 Tyrosinase inhibitor Proteins 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- NENOAJSZZPODGJ-OIMNJJJWSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] octanoate Chemical compound CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NENOAJSZZPODGJ-OIMNJJJWSA-N 0.000 description 1
- PGNYGWRFIFYBKV-UHFFFAOYSA-N [Mg].[Li].[Na] Chemical compound [Mg].[Li].[Na] PGNYGWRFIFYBKV-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229940048053 acrylate Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- BQMNFPBUAQPINY-UHFFFAOYSA-N azane;2-methyl-2-(prop-2-enoylamino)propane-1-sulfonic acid Chemical compound [NH4+].[O-]S(=O)(=O)CC(C)(C)NC(=O)C=C BQMNFPBUAQPINY-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 125000002511 behenyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940116365 diethylhexyl syringylidenemalonate Drugs 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940080812 glyceryl caprate Drugs 0.000 description 1
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 1
- 229940049290 hydrogenated coco-glycerides Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 229910052912 lithium silicate Inorganic materials 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229940100460 peg-100 stearate Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- LKUNXBRZDFMZOK-UHFFFAOYSA-N rac-1-monodecanoylglycerol Chemical compound CCCCCCCCCC(=O)OCC(O)CO LKUNXBRZDFMZOK-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 229940047670 sodium acrylate Drugs 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- FWFUWXVFYKCSQA-UHFFFAOYSA-M sodium;2-methyl-2-(prop-2-enoylamino)propane-1-sulfonate Chemical compound [Na+].[O-]S(=O)(=O)CC(C)(C)NC(=O)C=C FWFUWXVFYKCSQA-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940082787 spirulina Drugs 0.000 description 1
- 210000000438 stratum basale Anatomy 0.000 description 1
- 210000000498 stratum granulosum Anatomy 0.000 description 1
- 210000000439 stratum lucidum Anatomy 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Emergency Medicine (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
本发明提供了一种祛斑组合物,所述的祛斑组合物的各活性成分可以为:曲克芦丁、白薇提取物、水杨酸、4‑丁基间苯二酚。实验证明,活性成分能到达皮肤基底层,有效作用于黑色素细胞;通过功效测评,使用本发明实施例的祛斑精华液第1、4、8周后,呈现逐渐上升趋势,都具有显著统计学意义。使用产品后,ITA°值提升,说明本发明实施例提供的祛斑精华液能够显著改变皮肤肤色,具有祛斑效果。且本发明提供的祛斑组合物没有发现对皮肤有刺激性,不含有额外添加的水,活性物含量高。
Description
技术领域
本发明涉及化妆品领域,具体涉及一种祛斑组合物。
背景技术
黑色素是皮肤颜色的主要决定因素,它可以保护皮肤免受紫外线(UV)辐射50%至75%的吸收,并清除活性氧(ROS)。酪氨酸酶是一种含铜的单氧化酶,是催化黑色素细胞内黑色素合成的关键调节酶。该酶的主要作用是将 L-酪氨酸羟基化为 3,4-二羟基苯丙氨酸(L-DOPA),并随后将 L-DOPA 氧化成多巴醌。多巴醌是一种高活性化合物,可以自发聚合形成黑色素。然而,皮肤中黑色素的过量产生可能导致色素沉着过度。因此,酪氨酸酶抑制剂在化妆品和药物中作为增白剂和治疗色素沉着症如黄褐斑、痣和类似物变得越来越重要。
人体皮肤由表皮层和真皮层构成,其中表皮层包括角质层、透明层、颗粒层、基底层,其中角质层是表皮最外层,厚度约为 10-15μm,是大多数物质经皮运输的主要屏障。人体黑色素产生于黑色素细胞,而黑色素细胞分布于表皮层的基底层中,然而活性物难以到达基底层。
目前市面上的大多数祛斑产品都是通过抑制酪氨酸酶活性进而抑制黑色素合成从而实现美白功效的,没有考虑活性成分如何到达皮肤基底层,使酪氨酸酶抑制剂有效作用于黑色素细胞。因此,市面上的祛斑产品难以获得突出的祛斑效果。
发明内容
为了解决上述技术问题,申请人通过大量的试验,成功设计出一种含有曲克芦丁、白薇提取物、水杨酸等活性成分的祛斑组合物,其能够到达表皮基底层,有效作用于黑色素细胞,起到祛斑作用。
具体的,本发明涉及一种含有曲克芦丁、白薇提取物、水杨酸活性成分的祛斑组合物。
进一步地,以该祛斑组合物总质量为基准,所述祛斑组合物体系内的各活性成分的质量百分比优选范围为:曲克芦丁0.01-0.5%,优选0.1%;白薇提取物70-90%,优选80%;水杨酸0.01-0.5%,优选0.1%。
进一步地,所述祛斑组合物还可以包括4-丁基间苯二酚。
进一步地,所述祛斑组合物还可以包括保湿剂。
进一步地,所述祛斑组合物还可以包括增稠剂。
进一步地,所述祛斑组合物还可以包括防腐剂。
进一步地,所述保湿剂可以为甘油、1,3-丙二醇、1,2-丙二醇、丁二醇、双丙甘醇、甘油聚醚-26、山梨(糖)醇、双甘油、1,2-戊二醇、聚乙二醇-8、聚乙二醇-32、聚甘油-10、聚甘油-8、1,2-己二醇、异戊二醇、PPG-24-甘油聚醚-24、乙醇、辛甘醇、PEG/PPG-17/6 共聚物的一种或一种以上的混合。
进一步地,所述增稠剂可以是黄原胶、羟乙基纤维素、卡波姆、卡波姆钠、丙烯酸(酯)类共聚物、聚乙烯吡咯烷酮、硅酸铝镁、藻酸钠、丙烯酸(酯)类/C10-30 烷醇丙烯酸酯交联聚合物、硅酸钠镁锂、聚丙烯酸酯交联聚合物-6、聚丙烯酸钠接枝淀粉、羟丙基甲基纤维素、聚乙二醇-90M、丙烯酰二甲基牛磺酸铵/VP 共聚物、丙烯酸(酯)类/山嵛醇聚醚-25甲基丙烯酸酯共聚物、聚丙烯酸钠、结冷胶、果胶、透明质酸钠、聚谷氨酸钠、卡拉胶、刺槐豆胶、脱氢黄原胶、水解小核菌(SCLEROTIUM ROLFSSII)胶、小核菌(SCLEROTIUM ROLFSSII)胶、银耳(TREMELLA FUCIFORMIS)子实体提取物、皱波角叉菜(CHONDRUS CRISPUS)粉的一种或一种以上的混合。
进一步地,所述防腐剂可以是对羟基苯乙酮、辛酸甘油酯、癸酸甘油酯、亚丁香基丙二酸二乙基己酯、山梨坦辛酸酯、茴香酸、羟苯甲酯、羟苯丙酯、苯氧乙醇、辛甘醇、苯甲酸、氯苯甘醚中的一种或几种。
进一步地,以该祛斑组合物总质量为基准,所述保湿剂的质量百分比优选范围为:在该防腐体系的组分配置下,以该美白祛斑复合物总质量为基准,所述保湿剂的质量百分比优选范围为5-30%;所述增稠剂的质量百分比优选范围为0.05-0.5%;所述防腐剂的质量百分比优选范围为0.1-1%。
本发明还提供一种所述祛斑组合物在化妆品中的用途,进一步地,所述祛斑组合物至少可以用于制备面膜液、润肤水、润肤露、或精华。
本发明所述白薇提取物的制备方法可以包括如下步骤:(1)将白薇的根晒干,粉碎成10-50目粉末;(2)向粉末中加入50wt%丁二醇水溶液,料液比控制在1:(10-20),搅拌浸泡5-10小时,获得浸泡液;(3)将浸泡液100目滤布过滤;然后降温到1-5℃,静置10-20小时,再用1000目滤布过滤,即得。
经过大量试验,申请人发现本发明的祛斑组合物相较现有技术的方案,具有以下有益的技术效果:
(1)本发明提供的祛斑组合物的渗透性能良好,实验证明,其活性成分能到达皮肤基底层,有效作用于黑色素细胞;
(2)本发明提供的祛斑组合物祛斑效果突出。通过功效测评,使用本发明实施例的祛斑精华液第1、4、8周后,呈现逐渐上升趋势,都具有显著统计学意义。使用产品后,ITA°值提升,说明本发明实施例提供的祛斑精华液能够显著改变皮肤肤色,具有祛斑效果;
(3)本发明提供的祛斑组合物没有发现对皮肤有刺激性;
(4)本发明提供的祛斑组合物不含有额外添加的水,活性物含量高。
说明书附图
图1 样品对酪氨酸酶抑制效果。
具体实施方式
说明书中的实施方式仅用于对本发明进行说明,其并不对本发明的保护范围起到限定作用。本发明的保护范围仅由权利要求限定,在本发明公开的实施方式的基础上所做的任何省略、替换或修改将落入本发明的保护范围。
如本文所用术语“由…制备”与“包含”同义。本文中所用的术语“包含”、“包括”、“具有”、“含有”或其任何其它变形,意在覆盖非排它性的包括。例如,包含所列要素的组合物、步骤、方法、制品或装置不必仅限于那些要素,而是可以包括未明确列出的其它要素或此种组合物、步骤、方法、制品或装置所固有的要素。
当量、浓度、或者其它值或参数以范围、优选范围、或一系列上限优选值和下限优选值限定的范围表示时,这应当被理解为具体公开了由任何范围上限或优选值与任何范围下限或优选值的任一配对所形成的所有范围,而不论该范围是否单独公开了。例如,当公开了范围“1至5”时,所描述的范围应被解释为包括范围“1至4”、“1至3”、“1至2”、“1至2和4至5”、“1至3和5”等。当数值范围在本文中被描述时,除非另外说明,否则该范围意图包括其端值和在该范围内的所有整数和分数。
此外,本发明要素或组分前的不定冠词“一种”和“一个”对要素或组分的数量要求(即出现次数)无限制性。因此“一个”或“一种”应被解读为包括一个或至少一个,并且单数形式的要素或组分也包括复数形式,除非所述数量明显旨指单数形式。
为了加深对本发明的理解,下面将结合实施例对本发明作进一步详述,该实施例仅用于解释本发明,并不构成对本发明保护范围的限定。
本发明所述的白薇提取物的化妆品标准中文名称为白薇(CYNANCHUM ATRATUM)提取物。本发明实施例所涉及的白薇提取物通过如下方法制备得到:(1)将白薇的根晒干,粉碎成50目的粉末;(2)向粉末中加入50wt%丁二醇水溶液,料液比控制在1:15,搅拌下浸泡8小时,获得浸泡液;(3)将浸泡液100目滤布过滤;然后降温到3℃,静置15小时,再用1000目滤布过滤,即得。
本发明实施例所使用的水杨酸是环糊精包裹的50wt%含量的物质,通过环糊精的包裹可以增强水杨酸在水中的溶解度,有利于在水剂型配方中应用。合适的水杨酸可以是“TeeCycle SA”(来自广州汀兰生物科技有限公司)。
实施例1 酪氨酸酶抑制实验
酪氨酸酶可以催化 L-多巴生成多巴色素,多巴色素在 475 nm 处具有最大吸收。具体操作根据参考文献(丁小梅,何善生,王力,李健,李桂玲.螺旋藻多糖对酪氨酸酶的抑制作用及抗氧化性能[J].中国食品学报,2019,19(10):86-92.)所提供的方法:
(1)配制待测样品1-4,具体活性物质及质量比例如下表:
(2)取0.1mL的酪氨酸原酶溶液,与0.9 mL的PBS溶液(pH 6.8)混匀,在 0℃暂存。称取待测样品0.1g,0.3g,0.5g,0.7g,0.9g,1.0g,1.1g,1.3g,1.5g,2.0g,2.5g,用DMSO(二甲基亚砜)溶解,定容到25 m L容量瓶,配成不同剂量的抑制剂。准确移取一定量的0.5mmol/LL-多巴溶液,在30℃下水浴10 min。在比色皿中,加入2.8mL的L-多巴溶液,0.1mL待测效应物,混匀后调零,再加 0.1mL酪氨酸酶溶液,混匀后立即在 475nm波长进行连续扫描,得到吸光度与时间的变化关系曲线。同时用0.1mL不含效应物的DMSO空白对照,消光系数ε=3700L·mol-1·cm-1,直线的斜率为相对酶活,绘制相对酶活与待测样品浓度(CI)之间的关系图。
以酪氨酸酶相对活性对效应物(待测样品)浓度(CI)作图,如图1所示。从图1可见,酪氨酸酶活性与待测样品1-3的浓度成反比,而待测样品没有作用,说明曲克芦丁、白薇提取物有酪氨酸酶抑制作用,而水杨酸单独使用时没有效果。待测样品1的酪氨酸酶抑制效果明显比待测样品2-4要高,说明曲克芦丁、白薇提取物、水杨酸合用时效果更佳。
实施例2 体外透皮吸收实验
扩散池法是一种常规透皮吸收实验,它是将人或动物的离体皮肤安装在扩散池上,定时取接收液,用适宜的分析方法测定有效成分的含量,计算透皮速率来评价化学物的渗透特性。具体操作参考文献(梁乐谊,蔡慧娴,邓静茹,黄祥兴,温晓婷,卢秀霞.辛夷油微乳凝胶的研制及其药效学研究[J].中国新药杂志,2019,28(23):2899-2908.)所提供的方法:
(1)离体皮肤的处理:取健康SD大鼠(180~220) g,用无水乙醚将其麻醉,立即剃其腹部毛,待剃毛干净后脱臼处死,剪下并剥离腹部皮肤,除去皮下脂肪层和结缔组织,用生理盐水反复冲洗数遍直至干净,滤纸吸干,备用;
(2)标准曲线的建立:精密称取2.5mg待测样品(所述待测样品由质量之比为0.1:80:0.1的曲克芦丁、白薇提取物、水杨酸组成),20%乙醇-磷酸盐缓冲液(pH 7.4)溶解并定容至10mL,制得250μg·mL-1待测溶液。分别精密移取 0.4,0.6,0.8,1.0,1.2 和1.4 mL待测溶液,20%乙醇-磷酸盐缓冲液(pH 7.4)稀释并定容至10mL,制得质量浓度分别为10,15,20,25,30和 35μg·mL-1待测溶液。分别以空白接收液(20%乙醇-磷酸盐缓冲液,pH 7.4)为对照,于233.0 nm测定A2 值,以A2为纵坐标,待测溶液的质量C2为横坐标进行线性回归,得回归方程: A2 = 0.03608C2 +0.0201,r= 0.9997,结果待测溶液在10-35 μg·mL-1与吸光度呈良好的线性关系。
(3)透皮吸收实验:采用改良的 Franz扩散池,有效渗透面积A为2.0cm2,接收介质为20%乙醇-磷酸盐缓冲液(pH 7.4),使用前超声脱气30min,接收池体积为7.0mL。将处理好的离体大鼠腹部皮肤固定于供给池与接收池之间,角质层面向供给池,真皮层面向接收池,背面皮肤与接收液相接,除去气泡。分别取相当于待测液20 mg的20 mg·mL-1待测溶液1.0mL,置于供给池中,紧密贴敷在鼠皮上,使其均匀分布到鼠皮表面,平行 3 组,接收池中加入接收液,于(37±1)℃,200rpm转速下恒温磁力搅拌器中进行实验。分别于 0.5,1,2,3,4,6,8,10,12 和 24 h 取样3.0mL,同时补充相同温度下等体积的 20%乙醇-磷酸盐缓冲液(pH7.4),将取出的样品液经 0.45μm微孔滤膜过滤,弃去初滤液,取续滤液,以空白接收液为参照,于 233.0nm处测定A值。根据标准曲线计算相应时间点接收液中待测溶液的浓度,按以下公式计算各时间点药物单位面积的累积透皮渗透量(Qn)。
具体测试结果如下表:
从上表可见,待测样品(所述待测样品由质量之比为0.1:80:0.1的曲克芦丁、白薇提取物、水杨酸组成)的单位面积累积透皮渗透量在8小时内以较高的速度持续渗透,12小时后趋于平缓。
实施例3
一种祛斑精华液,包括如下质量百分含量的组分:
1,3-丙二醇5%、PEG/PPG-17/6 共聚物2%、1,2-戊二醇5%、PPG-24-甘油聚醚-24 1%、黄原胶0.05%、聚丙烯酸钠接枝淀粉0.1%、透明质酸钠0.02%、聚谷氨酸钠0.01%、丙烯酰二甲基牛磺酸铵/VP 共聚物0.2%、对羟基苯乙酮0.15%、曲克芦丁0.5%、水杨酸0.5%、白薇提取物70%、甘油聚醚-26 余量。
实施例4
一种祛斑精华液,包括如下质量百分含量的组分:
PEG/PPG-17/6 共聚物0.5%、甘油聚醚-26 2%、1,2-戊二醇0.5%、PPG-24-甘油聚醚-240.5%、黄原胶0.05%、透明质酸钠0.05%、聚谷氨酸钠0.05%、丙烯酰二甲基牛磺酸铵/VP 共聚物0.5%、羟苯甲酯0.15%、苯氧乙醇0.5%、氯苯甘醚0.1%、曲克芦丁0.01%、水杨酸0.01%、白薇提取物 90%、1,3-丙二醇 余量。
实施例5
一种祛斑精华液,包括如下质量百分含量的组分:
PEG/PPG-17/6 共聚物0.5%、甘油聚醚-26 2%、1,2-戊二醇0.5%、PPG-24-甘油聚醚-240.5%、黄原胶0.05%、透明质酸钠0.05%、聚谷氨酸钠0.05%、丙烯酰二甲基牛磺酸铵/VP 共聚物0.5%、羟苯甲酯0.15%、苯氧乙醇0.5%、氯苯甘醚0.1%、曲克芦丁0.1%、白薇提取物80%、水杨酸0.1%、1,3-丙二醇 余量。
实施例6
一种祛斑精华液,包括如下质量百分含量的组分:
PEG/PPG-17/6 共聚物0.5%、甘油聚醚-26 2%、1,2-戊二醇0.5%、PPG-24-甘油聚醚-240.5%、黄原胶0.05%、透明质酸钠0.05%、聚谷氨酸钠0.05%、丙烯酰二甲基牛磺酸铵/VP 共聚物0.5%、羟苯甲酯0.15%、苯氧乙醇0.5%、氯苯甘醚0.1%、曲克芦丁0.1%、4-丁基间苯二酚0.5%、白薇提取物80%、水杨酸0.1%、1,3-丙二醇 余量。
实施例7
一种祛斑霜,包括如下质量百分含量的组分:甘油5%、环五聚二甲基硅氧烷3%、鲸蜡硬脂醇3%、辛酸/癸酸甘油三酯5%、异十六烷1%、PEG-20 甲基葡糖倍半硬脂酸酯1%、甘油硬脂酸酯0.5%、PEG-100 硬脂酸酯0.2%、甲基葡糖倍半硬脂酸酯0.3%、氢化椰油甘油酯类1%、4-丁基间苯二酚0.5%、白薇提取物80%、水杨酸0.1%、生育酚(维生素E)、甘油葡糖苷0.5%、丙烯酸钠/丙烯酰二甲基牛磺酸钠共聚物0.3%、异十六烷0.5%、聚山梨醇酯-80 0.1%、卡波姆0.5%、尿囊素0.1%、三乙醇胺0.5%、甘油辛酸酯0.05%、辛酰羟肟酸0.05%、丙二醇1%、对羟基苯乙酮0.3%、透明质酸钠0.05%、水 余量。
实施例8
对实施例5所制得的祛斑精华液进行功效测评。具体操作参考团体标准(T/ZHCA 001-2018 化妆品美白祛斑功效测试方法)所提供的方法:
(1)志愿者:召集35名38-60岁的志愿者,志愿者均存在面部受试区域皮肤表皮色素沉着。其中2人由于时间关系原因未能完成所有随访,最终33人完成本次试验;
(2)使用方法:早晚各一次每次使用0.5g祛斑精华液,均匀涂抹于脸部,轻轻拍打至吸收;
(3)测试条件:测试环境温度20-22℃,相对湿度40-60%;
(4)测试方法:样品使用前,分别使用三刺激值比色计测量受试者样品涂抹区域和对照区域的ITA°值,在各测量区域内不同位置测量至少5次,取平均值,作为初始值。受试者连续使用产品第1周、第4周、第8周返回实验室,测量样品涂抹区域和对照区域的ITA°值,在各测量区域内不同位置测量至少5次,取平均值。具体测试结果如下表:
如上表可见,第0周时ITA°值最低,为30.6±1.9,使用本发明实施例的祛斑精华液第1、4、8周后,呈现逐渐上升趋势,都具有显著统计学意义。使用产品后,ITA°值提升,说明本发明实施例提供的祛斑精华液能够显著改变皮肤肤色,具有祛斑效果。
第8周对志愿者进行回访,没有人反馈产品有刺激过敏等异常情况。
以上实施例的各技术特征可以进行任意的组合,为使描述简洁,未对上述实施例中的各个技术特征所有可能的组合都进行描述,然而,只要这些技术特征的组合不存在矛盾,都应当认为是本说明书记载的范围。
以上实施例仅表达了本发明的几种实施方式,其描述较为具体和详细,但并不能因此而理解为对发明专利范围的限制。应当指出的是,对于本领域的普通技术人员来说,在不脱离本发明构思的前提下,还可以做出若干变形和改进,这些都属于本发明的保护范围。因此,本发明专利的保护范围应以所附权利要求为准。
Claims (9)
1.一种祛斑组合物,其特征在于,所述的祛斑组合物含有曲克芦丁、白薇提取物、水杨酸。
2.根据权利要求1所述的祛斑组合物,其特征在于,所述的水杨酸是环糊精包裹的50wt%含量的物质。
3.根据权利要求1所述的祛斑组合物,其特征在于,所述的曲克芦丁0.01-0.5%,优选0.1%;白薇提取物70-90%,优选80%;水杨酸0.01-0.5%,优选0.1%。
4.根据权利要求1所述的祛斑组合物,其特征在于,还包括4-丁基间苯二酚。
5.根据权利要求1所述的祛斑组合物,其特征在于,还包括保湿剂。
6.根据权利要求1所述的祛斑组合物,其特征在于,还包括增稠剂。
7.根据权利要求1所述的祛斑组合物,其特征在于,还包括防腐剂。
8.权利要求1-6任一项所述的祛斑组合物在化妆品中的用途,所述的化妆品为面膜液、润肤水、润肤露、或精华。
9.根据权利要求1所述的祛斑组合物,其特征在于,所述白薇提取物的制备方法包括如下步骤:(1)将白薇的根晒干,粉碎成10-50目粉末;(2)向粉末中加入50wt%丁二醇水溶液,料液比控制在1:(10-20),搅拌浸泡5-10小时,获得浸泡液;(3)将浸泡液100目滤布过滤;然后降温到1-5℃,静置10-20小时,再用1000目滤布过滤,即得。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010226078.0A CN111228158A (zh) | 2020-03-26 | 2020-03-26 | 一种祛斑组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010226078.0A CN111228158A (zh) | 2020-03-26 | 2020-03-26 | 一种祛斑组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111228158A true CN111228158A (zh) | 2020-06-05 |
Family
ID=70871435
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010226078.0A Pending CN111228158A (zh) | 2020-03-26 | 2020-03-26 | 一种祛斑组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111228158A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113208968A (zh) * | 2021-05-24 | 2021-08-06 | 杭州诺诚洗涤科技有限公司 | 一种美白保湿精华液及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1994272A (zh) * | 2006-01-05 | 2007-07-11 | 欧莱雅公司 | 薄荷提取物的化妆品应用 |
CN101926946A (zh) * | 2010-08-02 | 2010-12-29 | 陈敦华 | 一种具有美白、祛斑的药物组合物及其制备方法 |
KR20160090512A (ko) * | 2015-01-22 | 2016-08-01 | 주식회사 코리아나화장품 | 트록세루틴을 함유하는 피부 미백 화장료 조성물 |
CN108078877A (zh) * | 2017-12-04 | 2018-05-29 | 珠海伊斯佳科技股份有限公司 | 一种具有美白功效的中药组合物及其在化妆品中的应用 |
-
2020
- 2020-03-26 CN CN202010226078.0A patent/CN111228158A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1994272A (zh) * | 2006-01-05 | 2007-07-11 | 欧莱雅公司 | 薄荷提取物的化妆品应用 |
CN101926946A (zh) * | 2010-08-02 | 2010-12-29 | 陈敦华 | 一种具有美白、祛斑的药物组合物及其制备方法 |
KR20160090512A (ko) * | 2015-01-22 | 2016-08-01 | 주식회사 코리아나화장품 | 트록세루틴을 함유하는 피부 미백 화장료 조성물 |
CN108078877A (zh) * | 2017-12-04 | 2018-05-29 | 珠海伊斯佳科技股份有限公司 | 一种具有美白功效的中药组合物及其在化妆品中的应用 |
Non-Patent Citations (2)
Title |
---|
彭冠杰 等: "《美白化妆品科学与技术》", 30 June 2019, 中国轻工业出版社 * |
陈晓璐 等: "白薇经皮透过液对B16黑色素瘤细胞的作用", 《中国实验方剂学杂志》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113208968A (zh) * | 2021-05-24 | 2021-08-06 | 杭州诺诚洗涤科技有限公司 | 一种美白保湿精华液及其制备方法 |
CN113208968B (zh) * | 2021-05-24 | 2022-04-22 | 北京美丽臻颜化妆品有限公司 | 一种美白保湿精华液及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021031750A1 (zh) | 混合的桦树汁及其在护肤化妆品组合物中的应用 | |
US10532023B2 (en) | Camellia japonica extract and cosmetic compositions containing same | |
CN103816095A (zh) | 高级糖化终产物的去糖化 | |
KR20090130801A (ko) | 인삼씨 추출물을 함유하는 피부 외용제 조성물 | |
KR20100135871A (ko) | 섬유모세포의 증식 및/또는 활성을 자극하는 활성 성분 | |
JP7174736B2 (ja) | ダイダイの地上部の発酵抽出物 | |
JP2000191498A (ja) | コラ―ゲン産生促進剤および皮膚外用剤 | |
CN109106677B (zh) | 一种具有美白功能的组合物及其应用 | |
WO2015136198A1 (fr) | Utilisations cosmétiques de la swertiamarine | |
KR20130088912A (ko) | 텐저레틴 및 egcg를 함유하는 피부 외용제 조성물 | |
CN112587456A (zh) | 一种修护美白组合物及其制备方法 | |
CN115137667A (zh) | 一种具有促渗功效的化妆品组合物及其应用 | |
ES2741874T3 (es) | Uso de Tiliacora triandra en cosméticos y composiciones de los mismos | |
CH697417B1 (de) | Mittel zur Behandlung der Hautalterung enthaltend Paeoniflorin. | |
CN111228158A (zh) | 一种祛斑组合物 | |
JP5504389B2 (ja) | 皮膚保湿剤 | |
CN112386627A (zh) | 迷迭香愈伤组织汁液的用途以及用以诱导迷迭香愈伤组织的培养基 | |
CN110859756A (zh) | 一种促进冬虫夏草透皮吸收的液晶缓释体系及其制备方法和应用 | |
JP2002029923A (ja) | コラーゲン産生促進剤、エラスターゼ活性阻害剤、コラゲナーゼ活性阻害剤及び皮膚化粧料 | |
JP3441722B2 (ja) | 化粧料 | |
CN112294686B (zh) | 一种用于预防和/或改善肌肤老化的化妆品组合物及其用途 | |
KR102333132B1 (ko) | 프랜지패니 오일 또는 프랜지패니 오일의 발효물을 포함하는 화장료 조성물 | |
JP7289833B2 (ja) | 植物ゾウゲ抽出物(ファイテレファス属種(Phytelephas sp.))の化粧的使用 | |
KR100585613B1 (ko) | 베타-1,3-글루칸과 인삼사포닌을 함유하는 피부 외용제조성물 | |
JP2005029494A (ja) | メラノサイト増殖抑制剤およびこれを含む化粧料 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200605 |
|
RJ01 | Rejection of invention patent application after publication |